Log In
BCIQ
Print this Print this
 

LY2780301

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionSelective ATP competitive inhibitor against p70S6 kinase and protein kinase B (PKB; PKBA; AKT; AKT1)
Molecular Target S6 kinase (S6K) ; Protein kinase B (AKT) (AKT1) (PKB) (PKBA)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat advanced cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today